ABSTRACT: Segmental bone loss remains a challenging clinical problem for orthopaedic trauma surgeons. In addition to the missing bone itself, the local tissues (soft tissue, vascular) are often highly traumatized as well, resulting in a less than ideal environment for bone regeneration. As a result, attempts at limb salvage become a highly expensive endeavor, often requiring multiple operations and necessitating the use of every available strategy (autograft, allograft, bone graft substitution, Masquelet, bone transport, etc.) to achieve bony union. A cost-sensitive, functionally appropriate, and volumetrically adequate engineered substitute would be practicechanging for orthopaedic trauma surgeons and these patients with difficult clinical problems. In tissue engineering and bone regeneration fields, numerous research efforts continue to make progress toward new therapeutic interventions for segmental bone loss, including novel biomaterial development as well as cell-based strategies. Despite an ever-evolving literature base of these new therapeutic and engineered options, there remains a disconnect with the clinical practice, with very few translating into clinical use. A symposium entitled "Building better bone: The weaving of biologic and engineering strategies for managing bone loss," was presented at the 2016 Orthopaedic Research Society Conference to further explore this engineering-clinical disconnect, by surveying basic, translational, and clinical researchers along with orthopaedic surgeons and proposing ideas for pushing the bar forward in the field of segmental bone loss. ß
A 22-year-old patient presents to a trauma center after a motorcycle collision with a 25 cm laceration overlying his anteromedial tibia, 6 cm of segmental bone loss, and a cortical defect that spans five more centimeters (Fig. 1 ). This is a challenging and prevalent clinical problem in large orthopaedic trauma centers. The surgical and clinical approach is colored by extensive patient and family discussions, but is ultimately guided by the specific injuries to the soft and vascular tissues, the fracture pattern, and volume of bone loss. In the setting of "critical bone loss" (bone loss that does not heal without directed intervention, commonly characterized as >50% of osseous circumference or 2 cm longitudinally 1 ), surgeons counsel patients on the prolonged course to union, complications-including infection and nonunion-and multiple trips to the operating room to achieve union. This process is both physically and emotionally taxing to the patient and is costly to the healthcare system. 2 A cost-sensitive, functionally appropriate, and volumetrically adequate engineered bone substitute that can improve upon this long, complicated course would be practice-changing for orthopaedic traumatologists and patients, alike.
On the engineering front, from 1994 to 2014, the number of publications annually that contain the phrase "bone tissue engineering" has skyrocketed from just thirteen per year to 1,920 (Fig. 2) . The breadth and depth of research in this field, however, has not translated into clinical practice. To understand this translational bottleneck, a two-question survey given at the Workshop "Building better bone: The weaving of biologic and engineering strategies for managing bone loss" during the 2016 Orthopaedic Research Society Annual Meeting, sought to better define the disconnect between clinical and investigational experts (i.e., MDs and PhDs) regarding obstacles of managing critical bone loss. In this survey, while both groups agreed that infection is a yet-unconquered difficulty, MDs felt that fixation and clinical outcomes were significant barriers to success, while PhDs were more perturbed with tissue factors at the injured site (Table 1) . Surgeons most commonly noted cost as problematic, however, PhDs did not even note cost in their top five concerns. PhDs felt that biomaterials and in situ integration to be the largest challenges ( Table 2 ). The purpose of this article is to facilitate a joint discussion providing overlapping perspectives on strategies for managing bone loss, and outlining future directions for organized, united progress.
CLINICAL MANAGEMENT OF SEGMENTAL BONE LOSS: THE ROLE OF AUTOGRAFT, ALLOGRAFT, AND GRAFT SUBSTITUTES
For decision-making on bone graft choice, graft material and structural properties, as well as the capacity of the graft to form new bone (osteoconductivity, osteoinductivity, and osteogenicity) are carefully considered prior to clinical use. This is balanced with potential graft limitations (harvest site morbidity, limited amount of graft availability, local tissue reactivity, lack of receptiveness to orthopaedic implants, and infection). In a perfect world, a bone graft would quickly incorporate with the proposed fixation strategy, and provide structure, osteoconductive scaffolding, osteoinductive factors, and osteogenic cells-in a single-stage operation, without complication. The currently available options for managing bone loss each have advantages and disadvantages, and none provide this "perfect world" strategy.
Autograft
Autograft is the current benchmark-it provides osteoinductive, osteoconductive, and osteogenic properties. It can be derived from either cortical or cancellous bone and can be vascularized or nonvascularized.
Three common sources of autograft are iliac crest bone graft (ICBG), bone marrow aspirate concentrate (BMAC), vascularized bone graft, and long bone reaming, irrigating, and aspirating (RIA, Synthes Inc., West Chester, PA). ICBG is largely considered the "gold standard" for autograft selection, given the relative ease of harvesting and the volume of quality graft available. 3 It is rich in colony-forming progenitor cell number, which has been shown to directly correlate with the graft's healing potential. 4 A systematic review recently demonstrated one of the major disadvantages of ICBG-a harvest-site morbidity rate of nearly 20% ranging from minor (pain, mild gait abnormality, etc.) to major complications (deep infection, iatrogenic fracture, neurovascular injury, etc.). 3 ICBG has also been associated with increased hospital length of stay in spine patients, which leads to increased cost of care. 5 RIA is a relatively new method that can obtain large graft volumes, by harvesting bone from the medullary canal of long bones, typically the femoral or tibial shaft.
1 RIA can provide significantly more graft material, reported at twice that of ICBG (although clinically variable). 6 The biologic quality of RIAobtained tissue may also be more robust compared to ICBG, as same-patient comparisons revealed greater percentages of hematopoietic, vascular, and skeletal growth factors in RIA-obtained graft. 7 Therefore, RIA harvesting may have improved osteogenic and osteoinductive properties. 8 Further, tibial or femoral RIA has been shown to decrease operative time when compared with ICBG. 9 Despite apparent benefits of RIA, union rates and times were not significantly different from ICBG. 10 In addition, iatrogenic fracture is a possible risk of RIA that has mixed evidence, often tied to user error or inexperience. 11, 12 BMAC as is an isolated osteogenic/osteoinductive graft, used as a bone stimulating aid, often in conjunction with graft substitute. 13 An early, study of BMAC augmentation of distraction osteogenesis (DO) showed accelerated healing compared to augmentation with platelet rich plasma.
14 A randomized controlled trial demonstrated accelerated bone healing using BMAC delivered on a hydroxyapatite carrier (50-50% mixture) for a variety of skeletal defects. 13 The ability to augment autologous grafting aids in the treatment of larger bone defects and minimizes donor site morbidity for ICBG by reducing graft volume requirements. 15 The major downsides of BMAC are its lack of osteoconductivity, and lack of capacity to provide structural support.
Vascularized bone grafting is a technique that uses autogenous bone graft with an incorporated vascular pedicle, bypassing the need for osseointegration as a precursor for vascularization. It has shown improved survival of osteogenic graft cells, as well as faster time to union when compared to nonvascularized grafts in canine diaphyseal long bone fractures. 16 These grafts have revolutionized treatment of fractures with massive soft tissue injury, bony reconstruction, avascular necrosis, and common fractures with notoriously poor vascular supply. Downsides and complications to vascularized grafting include: The technical challenge of the surgery (requiring microvascular expertise to harvest and incorporate the graft into the defect), persistent bony defect/nonunion (the most prevalent complication) 17 ; mechanical dislodgment of the grafted bone, vascular failure, and infection. 18 Allograft Allograft is osteoconductive with variable osteoinductive properties. 19 Although allograft is abundantly available, and comes without harvest site morbidity, it is rarely used in isolation for segmental defects. This is due to poor inherent graft properties (weakly osteoinductive, 19 primarily osteoconductive), as well as risk of infection. 1 Cancellous allografts have greater remodeling capacity when compared to cortical allografts (by promoting further osteogenesis between trabeculae 20 ), but provide poor structural support. The low compressive strength of cancellous allograft makes it an unusable substitute in injuries that would be otherwise amenable to early weightbearing. 21, 22 Cortical allografts, on the other hand, are structural grafts that provide resistance to compressive loads. 20 However, the structural integrity gained with cortical grafting comes at the cost of decreased osteoconductive capacity due to dense tissue. 20 As such, cortical allografts are most useful for construct fortification, or to fill large defects as an onlay/strut graft for bones that do not require further remodeling. 20 Demineralized bone matrix (DBM) is an allograft that is obtained via acid extraction, and also is rarely used in isolation for traumatic segmental bone defects. DBM retains collagen and growth factors and can be prepared in various Bone quality and/or co-morbidities (7) Complex/multi-tissue injury (6) #3
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Fixation and mechanics (6) Fixation and mechanics (6) Efficacy/quality/supporting data (4) Mechanics (6) BUILDING BETTER BONE formulations, with reported enhancement of osteoinductive potential compared to standard allograft. 23 Clinical advantages of allograft, include abundant supply, and lack of harvest site morbidity. The cost of allografts, especially DBM, are high. For example, one study lists single-aliquot DBM costs ranging between $726-$1,375, with large segmental defects often requiring several aliquots to bridge the gap. 24 Similarly, single-use allograft materials ranged from $376-$2,230; while the majority of allograft material is less expensive than DBM, it still poses a substantial financial burden. 24 Bone Graft Substitutes Similar to allograft, bone graft substitutes are rarely clinically used in isolation for critical bone loss. The available options, including calcium sulfate and calcium phosphate, are osteoconductive substitutes that are typically used when autograft or allograft materials are volumetrically inadequate or unattainable. These substitutes typically act as "fillers" to augment structurally poor, but osteoinductive/genic-rich options (autograft or BMAC).
Current Limitations of Autograft, Allograft, and Bone Graft Substitutes For critically sized bone defects, autograft, allograft, and bone graft substitutes are infrequently used in isolation. Most commonly, the critical defects are accompanied by severely traumatized soft tissues, with varying degrees of contamination. Introducing autograft early in the course comes at the concern of "wasting" a precious resource in a hostile, infectionprone soft tissue environment. Commonly, autografting is performed for critical defects, but after a period of soft tissue recovery, and often in conjunction with the Masquelet technique described below.
CLINICAL MANAGEMENT OF SEGMENTAL BONE LOSS: THE ROLE OF MASQUELET AND BONE TRANSPORT
When standard grafting is inadequate, other methods that create in vivo bioreactors are employed. 1, 25 The induced membrane technique (of Masquelet) or DO are bioinductive and undergo a process of controlled fracture healing. They enable the surgeon to reconstruct large segments of bone and, with DO, restore length, alignment and rotation. However, those strengths are burdened by multiple procedures and lengthy recovery times. 1, 25 Induced Membrane Professor Masquelet introduced the induced membrane technique with the publication of his seminal series of 35 cases in 2000. 25 He utilized a two-stage technique, first with the insertion of a poly(methyl-methacrylate) spacer, allowing for the formation of a pseudosynovial membrane, followed by a delayed application of autologous bone graft within the membrane. This technique has been applied to defects ranging from 4 to 25 cm (Fig. 3) . This membrane technique has been studied in animal models and anatomic studies, showing creation of blood vessels, type I collagen, and macrophage proliferation; biologic studies showed production of BMP-2, VEGF, and mesenchymal stromal cells induced along the osteoblastic lineage within the membrane compartment. [26] [27] [28] Finally, patient studies have corroborated the experimental findings. 29 Interestingly, this activity is induced by a foreign body reaction itself, which modulates the activity of the membrane 30 -a possibly exploitable characteristic currently being investigated. Patel et al. showed that stem cells underwent distinct proliferation pathways depending on the presence of a foreign body in otherwise same tissue. 30 Strengths of this technique include eventual biologic incorporation of the graft and ability to span large segmental defects.
Distraction Osteogenesis
In 1905, Codivilla demonstrated that a bone could be lengthened by the serial application of casts attached to bed-frame traction. 31 In 1927, Abbot added pins, and in 1948, Allan incorporated a screw to allow for measured lengthening. 31 However, successful and reproducible clinical application did not occur until the 1950 when Ilizarov merged the technique with a meticulous osteotomy and a circular "ring" fixatorwhich became known as the "Ilizarov" technique. 32 Studies at the tissue, cellular and molecular levels have revealed that DO recapitulates many of the features of intramembranous and endochondral bone formation. 33 The technique, which begins by application of a ring fixator and osteotomy, goes through a latent phase (similar to a simple fracture) and finishes with a remodeling phase, but with a striking intermediate distraction phase in which bone is "grown" by controlled application of distractive forces (Fig. 4) . This phase is characterized by production of both inflammatory cytokines and growth factors including IL-6, IGF-1, group 1 BMPs, and VEGF, and by a robust increase in vascularity reflecting the high biologic activity. [34] [35] [36] The utilization of the "Ilizarov" technique requires little to no bone graft, and creates highly vascularized tissue for sizable defects, and often allows for immediate weight bearing on the affected limb.
Current Clinical Limitations of the Induced Membrane and Distraction Osteogenesis Techniques
For the "Masquelet," while the initial technique is able to salvage otherwise very difficult clinical situations, the average time to walking (8.5 months 37 ) is is a significant limitation along with the requisite multiple surgeries. The prolonged course to achieve union, via multiple surgeries, comes at an inherent cost. And while DO with a circular fixator allows for early weight bearing, patients are often hampered by distraction pain and pin-site infections, and is a tedious process (typically 1 mm per day) with mechanical instability that necessitates the circular fixator for 6-12 months. 38 In addition, the emotional cost to the patient (deemed "cage rage") from prolonged wear, as well as the financial cost device alone costs £9518 (approximately US$11,948), in addition to the prolonged course are high. 39 
CLINICAL MANAGEMENT OF SEGMENTAL BONE LOSS: THE ROLE OF ENDOPROSTHETICS
Endoprosthetic bone replacement, is a method of managing bone loss traditionally associated with tumor resection. Data surrounding the utility of endoprostheses in segmental bone loss is limited. However, potential advantages include early weight-bearing and the possibility of decreasing both the number of operations and the time to functional recovery. The major disadvantages to endoprostheses for bone loss in traumatic environments are cost and infection, which could lead to multistage exchange procedures with high failure rates.
T H E F O R E F R O N T O F E N G I N E E R I N G : BIOMATERIALS AND BIOLOGICAL CUES
There has been an expansion of the field of bone engineering in recent years; however, this growth has primarily been at the basic science and pre-clinical level. Clinical translation has been largely limited to bone void fillers and BMP (primarily delivered on very basic scaffolds). A few emerging areas from the engineers' perspective were highlighted in the ORS Workshop, including: additive manufacturing, vascularization strategies, mechanical loading and rehabilitation, and immunomodulation. The next section describes some current trends in engineering and summarizes challenges to clinical translation to facilitate future collaborative research.
Biomaterials
Biomaterials for bone tissue engineering have been reviewed in great depth over the last few years. [40] [41] [42] [43] These reviews outline key design principles: material choice, geometry, mechanical properties, degradation rate, and biologic/cell delivery. The choice of material for a bone tissue-engineering scaffold can be delineated into basic five material classifications: (i) grafts; (ii) metals; (iii) ceramics; (iv) polymers; and (v) composites. Each class comprises many formulations and fabrication strategies that significantly alter mechanical properties. When comparing mechanical properties of these materials (i.e., elastic modulus to ultimate strength) there is a wide spectrum of properties that have been used, ranging from soft materials (such as hydrogels), to materials with mechanical properties comparable to trabecular or cortical bone (such as ceramics and composites), to very stiff materials (such as metals), all of which have been used in bone tissue-engineering applications. 44 The variability between these types of scaffolds is often dictated by the goal of either a permanent or degradable implant. The architecture of the scaffold can also be used to direct the response of the tissue. Smooth solid surfaces will often result in a fibrous capsule forming at the interface between the scaffold and the native tissue. New approaches are utilizing surface modifications, ranging from topographical cues, to different types of coatings, to alterations in the surface roughness, to porous surface layers. 45, 46 Porous surface layers, for example, can enhance osseointegration at the interface, while maintaining the desired mechanical properties throughout the implant. 45 These design considerations directly influence one another, and must be part of a holistic approach that incorporates all considerations into a singular application. 
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Cells and Biological Cues
The key components of bone tissue engineering typically include both a biomaterial scaffold and the combination of cells or biological cues. The scaffold can be used to incorporate cells and different factors to enhance the way that they are delivered. For biological cues, these are typically growth factors, small molecules, or gene therapies, which are designed to target osteogenic and/or angiogenic mechanisms. These cues stimulate the host's endogenous repair mechanisms by recruiting cells, rather than requiring survival of exogenously implanted cells.
Key design criteria for the biological cues include the specific mechanism of action (targeting a specific pathway, recruiting endogenous cells, and directing a regenerative response), the specific factor (growth factors, cytokines, small molecules, gene therapies, etc.) and the controlled spatial and temporal presentation of the specific cue. 43, 47, 48 Other key considerations include potential side effects and the eventual cost. BMP's are the most commonly clinically utilized biological cue and are FDA-approved for a variety of bone indications. Clinically, BMPs are typically delivered on a collagen sponge, leading to a burst release with most of the growth factor being gone in a few days. Emerging approaches have utilized materials-based approaches to control the temporal and spatial presentation of BMP delivery. 49 A rational biomaterial design of the scaffold to deliver BMPs has shown the ability to reduce the dosage by an order of magnitude, and produce bone with better mechanical properties than autograft in pre-clinical models. 49 One of the clinical difficulties with BMP is that outcome studies examining the use of BMP in its current state for FDA-approved fracture indications (open tibia fractures for BMP-2 and recalcitrant nonunions for BMP-7) do not show a marked benefit in fracture healing times or rates of nonunion. 50 With the limited benefit and the high cost of BMP ($5,000 for single-use BMP-7), 24 many orthopaedic trauma surgeons have been deterred from routine (or even exceedingly rare with these authors) clinical use.
In incorporating cells into engineered scaffolds, key design criteria include: the manufacturing and production of the cells, the potency of the cells, and cell viability/survival. Many reviews have covered the spectrum of cell types that have been used for bone tissue engineering applications, 43 but these can broadly be broken down into stem/progenitor cell and differentiated cell types. Multiple stem cell types have been used including induced pluripotent stem cells, embryonic stem cells, neonatal (amniotic fluid or umbilical cord derived), or adult stem cells (bone marrow MSCs, adipose derived SCs, etc.). A direct comparison of adiposederived MSCs compared to bone marrow derived MSCs delivered in a hydrogel with low dose BMP-2 showed that bone marrow MSCs could potentiate the BMP-2 response while adipose-derived MSCs attenuated the response. 51 In addition, a variety of tissue cell types have been delivered, including: Osteoblasts, endothelial cells, and chondrocytes. Some studies have shown that delivering multiple cell types in conjunction, as well as optimization of timing of delivery, may be crucial for viability and eventual mineralization. 43 Further, the carrier plays a critical role in any cellbased engineering approach and can enhance cell survival/ viability and integration with the host tissue.
Another emerging trend in cell-based therapies is investigation into the manufacturing processes, to produce a consistent product at scale. This includes methods to isolate and expand cells while preserving and monitoring cell identity and purity, and then appropriate ways to handle the cells for storage and delivery. The manufacturing limitations around cell therapies have often been an afterthought to basic and translational research; however, this has been one of the predominant limitations in the translation of cell-based technologies. The National Cell Manufacturing Consortium recently released a roadmap produced by a combination of industry, academic and federal experts to outline key future directions for the field of cell manufacturing. 52 The clinical promise of utilizing engineered cell-based biomaterial composites is exciting, and has the potential to change clinical practice by providing a tunable, patient-specific material that provides all the advantages and none of the disadvantages of currently available clinical tools. Unfortunately, clinical translation is inextricably tied to the ability to mass-produce, store, and deliver a safe and reproducible product, which remains a current hurdle.
Emerging Trends
On the fundamental side of the field, some key emerging trends in bone tissue engineering research include additive manufacturing, [52] [53] [54] vascularization strategies, 55, 56 mechanical loading and rehabilitation, 57, 58 and immunomodulation. 59 Additive manufacturing is a promising approach for personalized bone tissue engineering scaffolds that are 3D-printed. 54 Custom geometries that are specific to the patient's injury or defect can be generated through presurgical imaging and planning. A patient-specific scaffold can then be printed using a variety of fabrication techniques using biomaterials that have tunable properties with high resolution and reproducibility. Studies have begun to directly compare different 3D printed materials and processes for bone applications. 60 While some of these materials and processes have translated into clinical applications, there are continuing questions about the outcome of the regulatory landscape for patient-specific applications, and approval of processes rather than a singular device. New directions in additive manufacturing include bioprinting, which combines additive manufacturing technologies, which print both materials and cells. 54 Recent work has even combined vascular channels and cell types into heterogenous scaffolds. 61, 62 The concept of 3D printing scaffolds, particularly with bioprinting capacity, is exciting to surgeons as no two bone defects are created the same. While segmental diaphyseal bone loss is less challenging from an anatomic reconstruction perspective (length, alignment, and rotation are the sole goals), the potential in osteoarticular bone loss is immense. Current clinical options for articular bone loss are extremely limited, and often require drastic procedures, including arthrodesis, or amputation surgery. Reinstitution of vascularity to injured tissues via grafts is needed to enhance bony integration and graft survival, improve the longevity and durability of the graft, and prevent infection. Tissue engineering approaches are now incorporating strategies to directly enhance or directly provide vascularization into the tissue-engineered graft. These strategies can include utilizing biologics (VEGF, FGF, IGF, synthetic peptides, etc.) and stem cells (MSCs or endothelial progenitor cells among others), creating complex pre-vascularized engineered structures, 56 or introducing neovascularization via a cartilage intermediate. 63 Recent studies have used pre-formed endothelial networks or microvascular fragments both of which can create a network in the graft that can quickly inosculate with the host vasculature upon implantation. 64, 65 Vascular networks are even being 3D printed into additive manufacturing structures to achieve this same goal. 66 Alternatively, researchers have taken cues from developmental biology processes and fracture healing, these new approaches have focused on engineering a cartilage template; a cartilage template may be more suitable for the initial hypoxic environment and subsequently be able to induce vascularization into the cartilage template and induce mineralization, remodeling, and the formation of functional bone. [67] [68] [69] Optimization of the mechanical environment is critical for bone homeostasis, with strategies like DO as described above currently in use clinically. Recent studies have investigated the control and measurement of the mechanical loading environment in bone tissue engineering. [70] [71] [72] [73] The environment needs to balance loading and the material properties of the graft, and the graft itself does not necessarily need to support loads. 71 This load-property balance must be considered for each graft type as healing, including inhibition of vascularization, and breakdown of soft hydrogel materials may result if inappropriately loaded. 74 The timing of loading in the healing cascade and the individualized graft effects need to be more rigorously evaluated prior to translational consideration. To do this, wireless miniaturized microelectromechanical systems (MEMS) sensors can be incorporated into graft materials to measure loading cues throughout the healing process. 73, 75, 76 A better engineering understanding of the mechanical requirements of individualized grafts and the ability to detect real-time environmental mechanical cues has the capacity to direct real-time important clinical decision-making (i.e., when can you weight bear?).
Finally, the role of the immune response in trauma, including acute inflammatory response, and subsequent regeneration is undergoing rigorous investigation in multiple engineering fields. 59, 77 For bone, recent studies have examined the role of altering macrophage phenotype, by affecting the transition from the inflammatory M1 to the pro-healing M2 in bone regeneration. 78 The next generation of tissue engineering strategies utilize immunomodulatory approaches to promote healing including via delivery of biological cues, cells and utilization of guided materials. In addition to the local environment, there is a growing recognition of the role BUILDING BETTER BONE of the systemic immune response in trauma, with the implication that optimization of the systemic response is necessary prior to introduction of any engineered construct. 79, 80 
CONCLUSIONS
Current patients who present to trauma centers with fractures and segmental bone loss face many challenges; these include both soft tissue and vascular considerations, as well as bone-specific challenges such as prolonged time to fracture union, the need for multiple surgeries, and the tremendously painful and costly nature of limb salvage. There is currently no "ideal" strategy for bone reconstruction for critical defects, and there is certainly no slam dunk algorithm, with patients often receiving a "kitchen sink" effort with many of the strategies described above (grafts, graft substitutes, induced membrane techniques, distraction osteogenesis). Each of these techniques has their own set of benefits and limitations as outlined. The promise of a patient specific engineered approach that enhances the benefits and eliminates the limitations of currently available therapies would be immediately practice-changing for orthopaedic trauma surgeons and their patients.
On the engineering side, a huge wave of engineering strategies has emerged, including biomaterials, cell-based therapies, and biological cues directed toward enhancing bone repair. Despite the interest, few have translated into clinical practice.
Why?
We propose that lack of communication between clinicians and engineers early in the pre-clinical investigative process is a significant problem. This disconnect was obvious in our survey collected during the ORS meeting, with a definite gap between clinicians and engineers regarding the remaining problems of treating bone loss. By facilitating discussions between clinicians and engineers early in the pre-clinical process, clinically relevant questions and design strategies can be implemented to better serve the true clinical void, and enhance translation of technology. The next generation of solutions must integrate the expertise of the physician, biologist, and engineer to create solutions that ultimately enhance our patients' lives.
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